MAZE director updates holdings after 1,489-share fund distribution

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director reports receipt of common stock through fund distribution. A Maze Therapeutics, Inc. (MAZE) director reported acquiring 1,489 shares of common stock on 11/19/2025 at a price of $0 per share, described as his pro rata share of a distribution from entities affiliated with Third Rock Ventures made for no consideration under an Exchange Act exemption. Following this transaction, he beneficially owns 31,113 shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998, for which he serves as trustee. This is a routine ownership reporting update rather than a new open-market purchase or sale.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider HOMCY CHARLES J

Role Director

Type	Security	Shares	Price	Value
Other	Common Stock	1,489	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 31,113 shares (Direct); Common Stock — 7,422 shares (Indirect, By Trust)

Footnotes (1)

1. The reported transaction represents the receipt by the reporting person of his pro rata share of a distribution made by one or more entities affiliated with Third Rock Ventures, for no consideration, of shares of the Issuer's common stock, which distribution was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended. These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is the trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/19/2025		J(1)		1,489	A	$0	31,113	D
Common Stock								7,422	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents the receipt by the reporting person of his pro rata share of a distribution made by one or more entities affiliated with Third Rock Ventures, for no consideration, of shares of the Issuer's common stock, which distribution was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

2. These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998, of which the reporting person is the trustee.

	/s/ Courtney Phillips, as attorney-in-fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Maze Therapeutics (MAZE) report on this Form 4?

A director of Maze Therapeutics reported receiving 1,489 shares of common stock on 11/19/2025 as part of a distribution from entities affiliated with Third Rock Ventures for no consideration.

What is the director’s total Maze Therapeutics (MAZE) share ownership after the transaction?

After the reported transaction, the director beneficially owns 31,113 Maze Therapeutics common shares directly and 7,422 shares indirectly through the Charles J. Homcy Revocable Trust UA 11/4/1998.

How did the Maze Therapeutics director receive the 1,489 shares reported on this Form 4?

The 1,489 shares were received as the director’s pro rata share of a distribution made by one or more entities affiliated with Third Rock Ventures, for no consideration, in reliance on Rule 16a-9 under the Securities Exchange Act.

Does the reported Maze Therapeutics (MAZE) transaction involve a cash purchase or sale?

No. The transaction is described as a distribution for no consideration, meaning the director did not pay cash for the 1,489 shares and it is not an open-market purchase or sale.

What indirect Maze Therapeutics holdings are disclosed for the reporting person?

The Form 4 states that 7,422 shares of Maze Therapeutics common stock are held indirectly by the Charles J. Homcy Revocable Trust UA 11/4/1998, for which the reporting person serves as trustee.

What role does the reporting person have at Maze Therapeutics (MAZE)?

The reporting person is identified as a director of Maze Therapeutics, Inc. and is filing the Form 4 as a single reporting person.